Medicine (Baltimore)
December 2021
Rationale: Guidelines of rare synchronous tumours treatment are often unavailable due to lack of wide prospective studies. Additionally, their management is not just a simple sum of coexisting tumours management and has to regard many circumstances like symptoms, age, comorbidities, advancement.
Patient Concerns: Herein, we report a case of an 81-year-old woman who presented with bleeding from the prolapsed uterus.
The selection of grass mixtures with appropriate visual and functional parameters for sowing football fields is a key element in shaping the sports infrastructure, ensuring the spectacularity of a match and comfort for players. The aim of the research was to investigate the properties of lawn grass mixtures and their suitability for football pitches. The experiment was conducted at the Toya Golf & Country Club (51° 20' E, 17° 07' N), Wrocław, Poland, between 2007 and 2009.
View Article and Find Full Text PDFBackground And Purpose: It is uncertain whether local control is acceptable after preoperative radiotherapy and local excision (LE). An optimal preoperative dose/fractionation schedule has not yet been established.
Material And Methods: In a phase III study, patients with cT1-2N0M0 or borderline cT2/T3N0M0 < 4 cm rectal adenocarcinomas were randomised to receive either 5 × 5 Gy plus 1 × 4 Gy boost or chemoradiation: 50.
Background: Improvements in local control are required when using preoperative chemoradiation for cT4 or advanced cT3 rectal cancer. There is therefore a need to explore more effective schedules.
Patients And Methods: Patients with fixed cT3 or cT4 cancer were randomized either to 5 × 5 Gy and three cycles of FOLFOX4 (group A) or to 50.
Purpose: To present an interim analysis of the trial comparing two neoadjuvant therapies for unresectable rectal cancer.
Methods: Patients with fixed cT3 or cT4 or locally recurrent rectal cancer without distant metastases were randomized to either 5 × 5 Gy and 3 courses of FOLFOX4 (schedule I) or 50.4 Gy delivered in 28 fractions given simultaneously with 5-Fu, leucovorin and oxaliplatin (schedule II).